Business Context and Reporting Period
This Form 8-K is filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on March 22, 2017. The report details a "Warrant Exercise Agreement" entered into on February 15, 2017, with institutional investors (Sabby Healthcare Master Fund Ltd. and Sabby Volatility Warrant Master Fund Ltd.) to incentivize the cash exercise of outstanding warrants.
Key Financial Metrics and Transactions
- Cash Proceeds: Approximately $564,000 received from the exercise of warrants for 104,419 shares on February 15, 2017. An additional $10,800 was received between March 10 and March 21, 2017, for 3,000 shares.
- Replacement Warrants Issued: 104,419 warrants issued at $4.99/share; 3,000 warrants issued at prices ranging from $2.03 to $3.77/share.
- Capital Structure Adjustments: Due to the issuance of Replacement Warrants at lower effective prices, the conversion price of Series C and Series D Convertible Preferred Stock was reset to $2.03 per share.
- Convertible Equity: As of March 22, 2017, 344.9 shares of Series C and 900 shares of Series D Preferred Stock are convertible into a total of 613,251 shares of common stock.
- Outstanding Warrants: The exercise price for 760,660 remaining warrants held by investors was reset to $2.03 per share.
Material Changes
The primary material change is the reduction of the exercise price for outstanding warrants and the conversion price for preferred stock to $2.03. This adjustment was triggered by the issuance of Replacement Warrants at prices lower than the previous effective prices. The filing notes that the Company removed warrant liability from its balance sheet to avoid future fair value adjustments and associated financial statement volatility.
Outlook, Risks, and Management Commentary
Management entered into the agreement to secure cash proceeds and eliminate warrant liability volatility. The Replacement Warrants differ from the original warrants in that their exercise price is not subject to reduction for subsequent equity issuances, and they do not allow investors to demand a purchase in the event of a fundamental transaction. The filing warns that if additional Replacement Warrants are issued at a lower price, the conversion and exercise prices will decrease further.
Investor Verification Checklist
- Verify the total number of shares issued upon warrant exercise and the total cash proceeds received.
- Confirm the new conversion price of $2.03 for Series C and Series D Preferred Stock and the resulting share count (613,251 shares).
- Review the terms of the Replacement Warrants to ensure they do not contain anti-dilution provisions.
- Monitor for future issuances of Replacement Warrants that could further reduce the exercise price of remaining warrants.
- Confirm the removal of warrant liability from the balance sheet in subsequent financial statements.